OBJECTIVE: Although there are still some controversies, large previous studies have confirmed that intravenous (i.v.) @entity927 ( @entity928 ) can effectively reduce @entity190 and transfusions in @entity572 ( @entity572 ) without increasing the risk of @entity1150 . However, few studies have investigated the combination of i.v. and topical application of @entity928 in primary @entity572 . The purpose of our current study is to examine whether i.v. combined with topical administration of @entity928 @entity86 and transfusion rates after @entity572 . METHODS: From December 2013 to May 2014, all adult @entity1 undergoing primary @entity572 at our arthroplasty center were considered for inclusion in the present study. Included @entity1 were randomly assigned to two groups by computer-generated list number: a @entity928 group and a placebo group. @entity1 in the @entity928 group received i.v. (15   mg/kg) combined with topical administration (1.0   g) of @entity928 during the @entity572 procedure, and @entity1 in the other group received the same dosage of normal saline both i.v. and topically. Our primary outcome measures were @entity190 (calculated using Gross's equation), hemoglobin, hematocrit and platelet concentration changes on the third postoperative day, the amount of drainage, the amount of intraoperative @entity190 , the frequency of transfusion, and the number of blood units transfused. Secondary outcome measures were the length of postoperative stay, range of hip motion (measured by goniometer), @entity572 ( @entity572 ), and any perioperative @entity532 or events such as @entity281 , @entity11942 or PE. Range of motion and @entity572 were measured at 3   week follow-up and compared with preoperative values. RESULTS: This trial included 100 @entity1 (50 in each group). @entity1 in the @entity928 group had significantly higher postoperative hemoglobin (103 vs 87.7   g/dL, P < 0.01), lower hemoglobin changes (32.2 vs 44.9   g/dL, P < 0.01), higher postoperative hematocrit (0.32 vs 0.27   L/L, P < 0.01), lower hematocrit changes (0.1 vs 0.14   L/L, P < 0.01), @entity190 (822 vs 1100   mL, P = 0.004), lower drainage (117.8 vs 242.4   mL, P < 0.01), lower intraoperative @entity190 (193.8 vs 288.2   mL, P < 0.01), and lower transfusion rate (2% vs 34%, P < 0.01) compared with those in the placebo group. No statistical difference was found in postoperative platelets between the two groups. There were no differences in perioperative @entity532 or @entity1211 ( @entity1211 ) events. CONCLUSIONS: The combined administration of i.v. and topical @entity928 resulted in a clinically relevant reduction in @entity190 , compared with placebo group. No @entity1031 @entity532 were observed. This randomized controlled trial supports the combined i.v. and topical administration of @entity928 in primary @entity572 .

Intravenous Combined with Topical Administration of XXXX in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss', 'lower total blood loss', 'total blood loss'] @entity532 :: ('MESH:D003925', 'Disease') :: ['complications'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity572 :: ('MESH:D006617', 'Disease') :: ['HHS', 'THA', 'total hip arthroplasty', 'Harris hip scores'] @entity86 :: ('MESH:D019106', 'Disease') :: ['decreases postoperative blood loss'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism'] @entity11942 :: ('OMIM:612862', 'Disease') :: ['DVT']
@entity927 :: (MESH:D014148,Chemical) :: ['Tranexamic Acid']
